Current guidelines say patients should stop taking Galantamine (Reminyl) when they have deteriorated past a certain point, and are unable to walk without assistance, bathe or dress themselves.
But a new study published in the Lancet Neurology journal shows that severely ill people can still benefit from taking the drug, as it can improve their movement, memory and awareness of the world around them. It also improves the mortality rate of sufferers.
Campaigners say the findings should lead to a revision of the guidelines by the National Institute for Health and Clinical Excellence (Nice), which rules on the cost effectiveness of treatments.
They say the study supports their call for......read the whole article